May 2026 Stryker completed the acquisition of Amplitude Vascular Systems, adding next-generation intravascular lithotripsy (IVL) technology to strengthen its portfolio for treating complex peripheral artery disease (PAD).
June 2025 The European Medicines Agency (EMA) issued a positive opinion to update the label for Novo Nordisk's Ozempic® (semaglutide) to include treatment of symptomatic peripheral artery disease in adults with type 2 diabetes, based on improved walking-distance outcomes in late-stage clinical trials.
May 2025 Medtronic received U.S. FDA approval for manufacturing process updates to its IN.PACT AV Paclitaxel-Coated PTA Balloon Catheter, supporting continued production of its PAD treatment device portfolio.